August 20, 2009

Fixed- or Controlled-Dose Mycophenolate Mofetil with Standard- or Reduced-dose Calcineurin Inhibitors: The Opticept Trial


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Mycophenolate mofetil is usually given at a fixed-dose post-transplant, with dose reductions made only for toxicity. This is the third randomized-controlled trial to assess a strategy of dose adjustment based on drug levels. Concentration-controlled MMF combined with lower-dose calcineurin inhibitors was non-inferior to fixed-dose MMF and standard-dose calcineurin inhibitors, with a trend to improved renal function but no difference in MMF-related adverse effects.

Renal Transplantation